Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.9
7.8
Journals
Vaccines
Special Issues
Advances in Cancer Vaccines: From Bench to Bedside
share announcement

Advances in Cancer Vaccines: From Bench to Bedside

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 639

Special Issue Editors

Prof. Dr. Qizhi Cathy Yao

E-Mail Website
Guest Editor
1. Michael E. DeBakey Department of Surgery, Division of Surgical Oncology, Baylor College of Medicine, Houston, TX 77030, USA
2. Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. DeBakey VA Medical Center, Houston, TX 77030, USA
Interests: HIV vaccines; pancreatic cancer pathogenesis and therapy; nanoparticle targeted delivery; virus-like particles; cancer immunotherapy; tumor microenvironment
Special Issues, Collections and Topics in MDPI journals
Dr. Alok K. Mishra

E-Mail Website
Guest Editor
Department of Molecular Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA, USA
Interests: immuno-oncology; immunotherapy; cancer vaccines; gene editing; preclinical development
Dr. Sunil K. Malonia

E-Mail Website
Guest Editor
Department of Molecular Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA, USA
Interests: immuno-oncology; cancer biology; gene editing; gene therapy; viral vectors; preclinical development

Special Issue Information

Dear Colleagues,

Cancer remains a major health burden globally, and innovative approaches for the prevention and treatment of it are urgently needed. Cancer vaccines have the potential to revolutionize cancer therapy by harnessing the patient's immune system to target cancer cells.

This Special Issue will cover the latest progress in cancer vaccine research and developments. We aim to provide a comprehensive overview of recent developments in cancer vaccines, including novel targets, formulations, and delivery systems. Furthermore, we intend to explore the potential of combination therapies that incorporate cancer vaccines and the identification of biomarkers to guide patient selection and monitoring. Additionally, the Special Issue will cover the research on mRNA-based cancer vaccines, which represent a promising new approach to cancer immunotherapy due to their flexibility and speed of development.

This Special Issue will be of immense interest to researchers, clinicians, and policymakers involved in cancer immunotherapy, and it is hoped that it will make a significant contribution to the field of cancer therapy.

We invite submissions of original research articles, reviews, and perspectives that provide insights into cancer vaccine development, immune correlates of protection, regulatory and ethical considerations, and other relevant topics. This Special Issue will be of interest to researchers, clinicians, and policymakers involved in cancer therapy.

We believe that this Special Issue will make a significant contribution to the field of cancer immunotherapy and have a positive impact on patient outcomes. We look forward to your contributions and collaboration.

Prof. Dr. Qizhi Cathy Yao
Dr. Alok K. Mishra
Dr. Sunil K. Malonia
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immunotherapy
  • tumor antigens
  • antigen presentation
  • clinical trials
  • personalized medicine
  • cancer immunology
  • cancer treatment
  • precision medicine
  • biomarkers

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 3791 KiB  
Article
Nano-Pulse Treatment Overcomes the Immunosuppressive Tumor Microenvironment to Elicit In Situ Vaccination Protection against Breast Cancer
by Anthony Nanajian, Megan Scott, Niculina I. Burcus, Brittney L. Ruedlinger, Edwin A. Oshin, Stephen J. Beebe and Siqi Guo
Vaccines 2024, 12(6), 633; https://doi.org/10.3390/vaccines12060633 - 7 Jun 2024
Viewed by 313
Abstract
We previously reported that nano-pulse treatment (NPT), a pulsed power technology, resulted in 4T1-luc mammary tumor elimination and a strong in situ vaccination, thereby completely protecting tumor-free animals against a second live tumor challenge. The mechanism whereby NPT mounts effective antitumor immune responses [...] Read more.
We previously reported that nano-pulse treatment (NPT), a pulsed power technology, resulted in 4T1-luc mammary tumor elimination and a strong in situ vaccination, thereby completely protecting tumor-free animals against a second live tumor challenge. The mechanism whereby NPT mounts effective antitumor immune responses in the 4T1 breast cancer predominantly immunosuppressive tumor microenvironment (TME) remains unanswered. In this study, orthotopic 4T1 mouse breast tumors were treated with NPT (100 ns, 50 kV/cm, 1000 pulses, 3 Hz). Blood, spleen, draining lymph nodes, and tumors were harvested at 4-h, 8-h, 1-day, 3-day, 7-day, and 3-month post-treatment intervals for the analysis of frequencies, death, and functional markers of various immune cells in addition to the suppressor function of regulatory T cells (Tregs). NPT was verified to elicit strong in situ vaccination (ISV) against breast cancer and promote both acute and long-term T cell memory. NPT abolished immunosuppressive dominance systemically and in the TME by substantially reducing Tregs, myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs). NPT induced apoptosis in Tregs and TAMs. It also functionally diminished the Treg suppression capacity, explained by the downregulation of activation markers, particularly 4-1BB and TGFβ, and a phenotypic shift from predominantly activated (CD44+CD62L−) to naïve (CD44−CD62L+) Tregs. Importantly, NPT selectively induced apoptosis in activated Tregs and spared effector CD4+ and CD8+ T cells. These changes were followed by a concomitant rise in CD8+CD103+ tissue-resident memory T cells and TAM M1 polarization. These findings indicate that NPT effectively switches the TME and secondary lymphatic systems from an immunosuppressive to an immunostimulatory state, allowing cytotoxic T cell function and immune memory formation to eliminate cancer cells and account for the NPT in situ vaccination. Full article
(This article belongs to the Special Issue Advances in Cancer Vaccines: From Bench to Bedside)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop